- 1 Tryptophan metabolism determines outcome in tuberculous meningitis: a
- 2 targeted metabolomic analysis
- 3

Edwin Ardiansyah<sup>1,2</sup>, Julian Avila Pacheco<sup>3</sup>, Le Thanh Hoang Nhat<sup>4</sup>, Sofiati Dian<sup>1,6</sup>, Dao Nguyen Vinh<sup>4</sup>, Hoang Thanh Hai<sup>4</sup>, Kevin Bullock<sup>3</sup>, Bachti Alisjahbana<sup>1,5</sup>, Mihai G Netea<sup>2</sup>, Riwanti Estiasari<sup>7</sup>,
Trinh Thi Bich Tram<sup>4</sup>, Joseph Donovan<sup>4,8,9</sup>, Dorothee Heemskerk<sup>10</sup>, Tran Thi Hong Chau<sup>4,11</sup>,
Nguyen Duc Bang<sup>12</sup>, Ahmad Rizal Ganiem<sup>1,6</sup>, Rovina Ruslami<sup>1,13</sup>, Valerie ACM Koeken<sup>2,14</sup>, Raph L
Hamers<sup>15</sup>, Darma Imran<sup>7</sup>, Kartika Maharani<sup>7</sup>, Vinod Kumar<sup>2</sup>, Clary B. Clish<sup>3</sup>, Reinout van Crevel<sup>2</sup>, Guy
Thwaites<sup>4,8</sup>, Arjan van Laarhoven<sup>2,\*,#</sup> & Nguyen Thuy Thuong Thuong<sup>4,8,\*</sup>

- 10 \* equal contribution
- 11 # corresponding author

# 12 Affiliations

- 13 1. Research Center for Care and Control of Infectious Diseases, Universitas Padjadjaran, Bandung, 14 Indonesia 15 2. Department of Internal Medicine and Radboud Center of Infectious Diseases (RCI), Radboud 16 University Medical Center, Nijmegen, Netherlands 17 3. The Broad Institute of MIT and Harvard, Cambridge, MA, USA 4. Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; 18 5. Department of Internal Medicine, Hasan Sadikin Hospital, Faculty of Medicine, Universitas 19 20 Padjadjaran, Bandung, Indonesia Department of Neurology, Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, 21 6. 22 Bandung, Indonesia 23 7. Department of Neurology, Cipto Mangunkusumo Hospital, Faculty of Medicine Universitas Indonesia 8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of 24 25 Oxford, Oxford, United Kingdom 26 9. London School of Hygiene and Tropical Medicine, Keppel St, London, United Kingdom 10. Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical 27 28 Centre, Amsterdam, the Netherlands 29 11. Hospital for Tropical Diseases, District 5, Ho Chi Minh City, Vietnam 30 12. Pham Ngoc Thach Hospital for Tuberculosis and Lung Disease, District 5, Ho Chi Minh City, Vietnam 31 13. Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia 14. Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised 32 33 Infection Medicine (CiiM) & TWINCORE, joint ventures between the Helmholtz-Centre for Infection 34 Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany 15. Oxford University Clinical Research Unit Indonesia, Faculty of Medicine Universitas Indonesia 35
- 36

# 37 Abstract

# 38 Background

Cellular metabolism is critical for the host immune function against pathogens, and metabolomic analysis may help understand the characteristic immunopathology of tuberculosis. We performed targeted metabolomic

40 analyses in a large cohort of patients with tuberculous meningitis (TBM), the most severe manifestation of

42 tuberculosis, focusing on tryptophan metabolism.

# 43 Methods

We studied 1069 Indonesian and Vietnamese adults with TBM (26.6% HIV-positive), 54 non-infectious controls, 50 with bacterial meningitis, and 60 with cryptococcal meningitis. Tryptophan and downstream metabolites were measured in cerebrospinal fluid (CSF) and plasma using targeted liquid chromatography mass-spectrometry. Individual metabolite levels were associated with survival, clinical parameters, CSF bacterial load and 92 CSF inflammatory proteins.

# 49 Results

50 CSF tryptophan was associated with 60-day mortality from tuberculous meningitis (HR=1.16, 95%CI=1.10-1.24, 51 for each doubling in CSF tryptophan) both in HIV-negative and HIV-positive patients. CSF tryptophan 52 concentrations did not correlate with CSF bacterial load nor CSF inflammation but were negatively correlated 53 with CSF interferon-gamma concentrations. Unlike tryptophan, CSF concentrations of an intercorrelating 54 cluster of downstream kynurenine metabolites did not predict mortality. These CSF kynurenine metabolites 55 did however correlate with CSF inflammation and markers of blood-CSF leakage, and plasma kynurenine 56 predicted death (HR 1.54, 95%CI=1.22-1.93). These findings were mostly specific for TBM, although high CSF tryptophan was also associated with mortality from cryptococcal meningitis. 57

# 58 Conclusion

59 TBM patients with a high baseline CSF tryptophan or high systemic (plasma) kynurenine are at increased risk of 60 mortality. These findings may reveal new targets for host-directed therapy.

# 61 Funding

This study was supported by National Institutes of Health (R01Al145781) and the Wellcome Trust (110179/Z/15/Z and 206724/Z/17/Z).

64

65

#### Introduction 67

68 Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis affecting approximately 69 160,000 adults each year.<sup>1</sup> Patients suffer from varying degrees of intracerebral inflammation, commonly 70 manifest as leptomeningitis, vasculitis and space-occupying brain lesions (tuberculomas). Hydrocephalus, stroke, seizures, focal neurological deficits, and loss of consciousness are common complications and lead to 71 death in around 30% of patients, even when treated with anti-tuberculosis drugs and adjuvant corticosteroid 72 73 therapy.<sup>1</sup> Development of more effective host-directed therapy is hampered by a lack of knowledge on the biological pathways involved in the immunopathology of TBM.<sup>2</sup> 74

75 Metabolism is critical for the function of immune cells, and analysis of cerebrospinal fluid (CSF) metabolites 76 could help unravel underlying biological mechanisms in TBM. Previously, using a large-scale metabolomics analysis, we found that lower cerebrospinal fluid (CSF) tryptophan concentrations were associated with 77 survival of TBM patients in Indonesia.<sup>3</sup> This study did not include HIV-infected patients and the association was 78 not validated in other populations.<sup>4,5</sup> Moreover, there is a need to investigate the downstream metabolites in 79 the kynurenine pathway (Figure 1), through which 95% of tryptophan is initially catabolized via indoleamine 80 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) and which includes metabolites with putative 81 neuroprotective (e.g. kynurenic acid) or neurodamaging (e.g. quinolinic acid) properties.<sup>6</sup> Lastly, there is a 82 83 need to compare these findings in other neuro-infectious diseases to distinguish disease specific from broader 84 mechanisms.

85 We therefore sought to define and validate the relationship between tryptophan and its metabolites and 86 survival from TBM in large, independent populations, including HIV-positive individuals. We aimed to confirm that a higher CSF tryptophan would predict higher mortality across different populations and we hypothesized 87 that high tryptophan would be associated with a higher CSF bacterial load, more inflammation and lower 88 89 downstream kynurenine metabolites. We lastly sought to investigate how systemic (plasma) metabolite 90 concentrations linked to outcome.

T cell

niacinamide

kynurenic acid

quinolinic acid



N-acetylserotonin

91



5-hydroxytryptophol

93 Figure 1 Tryptophan metabolism pathway. Tryptophan is metabolized mainly through the kynurenine 94 pathway through indoleamine 2,3-dioxygenase 1 (IDO1), generating kynurenine and its downstream 95 metabolites (blue box). IDO1 is partly stimulated by M. tuberculosis-induced interferon gamma (IFN-y) 96 production by T helper 1 cells.

3-hydroxyanthranilic

acid

## 98 Materials and Methods

#### 99 Setting and Patients

Patients with subacute meningitis were included from the Hospital for Tropical Diseases and Pham Ngoc Thach 100 Hospital for Tuberculosis and Lung Disease in Ho Chi Minh City, Vietnam between 2011-2014,<sup>4,7</sup> and Hasan 101 Sadikin hospital in Indonesia between 2007-2019.<sup>3,5</sup> TBM patients were defined as having 'definite TBM' if they 102 had either microbial confirmation by Ziehl-Neelsen staining, positive CSF culture or GeneXpert. Based on 103 104 previous studies,<sup>5</sup> probable TBM was defined as clinically suspected TBM fulfilling at least 2 out of the 105 following 3 criteria: CSF leukocytes  $\geq$  5 cells/ $\mu$ L, CSF/blood glucose ratio < 0.5, and CSF protein > 0.45 g/L. Patients were treated with antibiotics according to national guidelines for 180 days minimally, and received 106 adjunctive dexamethasone starting at 0.3 mg/kg for grade I and 0.4 mg/kg for grade II or III 107 108 tuberculous meningitis and tapered thereafter.<sup>8</sup> Patients were followed-up clinically or by phone up until day 109 180 from admission. Primary outcome was 60-day survival, when most deaths attributable to TBM occur. As a 110 secondary endpoint, earlier and later mortality were explored separately. We ensured equal power for both 111 time windows by separating them by the median time to death for those patients who died during the total 112 follow up of 180 days.

113 Patients without an infection (non-infectious controls) were included from the same sites. In Indonesia, 114 patients in this group had undergone a lumbar puncture for suspected central nervous system infection or 115 subarachnoid bleeding, but infection was excluded by negative microscopy, GeneXpert and bacterial culture, 116 and CSF leucocytes < 5 cells/ $\mu$ L and CSF/blood glucose ratio  $\geq$  0.5. In Vietnam, patients were included as 117 controls if they had undergone a lumbar puncture, but an alternative, non-infectious, diagnosis was confirmed. 118 In both sites, none of the non-infectious controls received anti-tuberculosis treatment. HIV-negative patients 119 with microbiologically confirmed bacterial meningitis and HIV-positive patients with cryptococcal meningitis 120 patients were included from the same sites.

121 Ethical approval was obtained from the Ethical Committee of Hasan Sadikin Hospital, Faculty of 122 Medicine, Universitas Padjadjaran, Bandung, Indonesia and from the Oxford Tropical Research Ethics 123 Committee in the United Kingdom, the Institutional Review Boards of the Hospital for Tropical Diseases and 124 Pham Ngoc Thach Hospital in Vietnam. Written (Vietnam) or oral (Indonesia) consent to be included in the 125 study, for storage of surplus sample, and to obtain follow-up data was obtained from patients or close 126 relatives of patients who were unconscious. The paper adheres to the STROBE methodology.

#### 127 Metabolite measurements

128 CSF and blood samples were centrifuged for 15 minutes according to local protocols (865 - 3000 x g) and 129 supernatants were stored at -80'C.9 CSF and plasma metabolites were measured using targeted a liquid 130 chromatography tandem mass spectrometry (LC-MS) method with a system comprised of a 1290 Infinity II U-131 HPLC coupled to an Agilent 6495 Triple Quadrupole mass spectrometer (Agilent Tech. Santa Clara, CA). 132 Metabolites were extracted from plasma or CSF (10 µL) using 90 µL of acetonitrile/methanol/formic acid 133 (74.9:24.9:0.2 v/v/v) containing stable isotope-labeled internal standards (valine-d8, Sigma-Aldrich; St. Louis, 134 MO; and phenylalanine-d8, Cambridge Isotope Laboratories, Andover, MA). The samples were centrifuged (10 135 min, 9,000 x g, 4°C), and the supernatants were injected directly onto a 150 x 2 mm, 3 µm Atlantis HILIC 136 column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 250 μL/min with 5% 137 mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 0.5 minute followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. Pairs of pooled samples 138 139 generated using aliquots of all samples in the study were included every 20 samples correct for MS sensitivity 140 drift and for quality control analyses. Sample stability over the 7 years study inclusion and 4-year storage time was checked by plotting metabolite levels of definite TBM patients against storage time. Tryptophan 141 142 metabolites were measured using the following multiple reaction monitoring transitions: 3-hydroxyanthranilic 143 acid (154.1 -> 136.0), 3-indoleacetic acid (176.1 -> 130.1), 3-methoxyanthranilate (168.1 -> 150.0), 5-144 hydroxyindoleacetic acid (192.1 -> 146.0), 5-methoxytryptophol (192.1 -> 130.0), kynurenic acid (190.1 -> 145 144.1), kynurenine (209.1 -> 94.0), tryptophan (205.1 -> 187.9), N-acetylserotonin (219.1 -> 160.0), 146 niacinamide (123.1 -> 80.1), quinolinic acid (168.0 -> 149.9) and xanthurenic acid (206.1 -> 132.0). Absolute concentrations were determined using external calibration curves created via serial dilution of stable isotope-147 labeled compounds in CSF and plasma. These compounds were sourced from Cambridge Isotope Labs: 3-148 indoleacetic acid-d7 (DLM-8040), anthranilic acid-<sup>13</sup>C6 (CLM-701), 5-HIAA-<sup>13</sup>C6 (CLM-9936), kynurenic acid-d5 149 (DLM-7374), L-kynurenine-d6 (DLM-7842), L-tryptophan-<sup>13</sup>C11 (CLM-4290) and niacinamide-<sup>13</sup>C6 (CLM-9925). 150

151 Peak abundances were manually integrated using the MassHunter software provided by the LC-MS 152 manufacturer.

#### 153 CSF mycobacterial load and inflammatory proteins

The CSF mycobacterial load was inferred qualitatively by comparing patients with negative versus positive CSF 154 culture, and semiquantitively from the GeneXpert Ct-values as described previously,<sup>10</sup> and inferred from CSF 155 M. tuberculosis culture. CSF inflammatory cytokines in 178 Indonesian HIV-negative TBM patients were 156 157 measured using a multiplex proximity extension assay (Olink) in two batches. Olink uses a multiplex assay that 158 simultaneously recognize 96 target proteins through specific paired-antibodies which are coupled with unique oligonucleotides, for quantitative PCR measurement.<sup>11</sup> For each protein, overlapping samples from two 159 160 batches were fitted in a linear regression model, where the linear components were subsequently extracted, 161 and used as correction factors for batches normalization. In 304 Vietnamese HIV-negative patients, 10 human 162 cytokines were measured in CSF with Luminex multiplex bead array technology (Bio-Rad Laboratories, 163 Hercules, CA).<sup>4</sup> CSF total protein was used as proxy for blood-CSF barrier disruption as it showed a near-perfect correlation with the established marker CSF-serum albumin (r<sup>2</sup>=0.98).<sup>12</sup> 164

#### 165 Quality control and statistical analysis

166 Only metabolites and proteins with a coefficient of variation (CV) of the pooled samples < 30% and < 25% 167 missing values, respectively among TBM patients were further included in the analysis. Remaining missing metabolite values after quality control were replaced with half of the minimum measured value of the 168 corresponding metabolite, and log2-transformed subsequently. Statistical analyses were performed in R 169 170 4.0.4<sup>13</sup>, using the R packages survival, tableone, dplyr, openxlsx, pheatmap, grid, and ggplot2. Correlation analyses between metabolites levels, and between metabolites levels and clinical and inflammatory 171 172 parameters, were calculated using spearman-rank correlation. The impact of baseline CSF and plasma 173 metabolite levels on 60-day survival was tested in a Cox-regression model, adjusted for sex, age, and HIV 174 status as covariates. The model stratified by study site as mortality is known to be higher in the Indonesian<sup>5</sup> 175 than in the Vietnamese' cohort. An analysis plan was made before the study, and correction for multiple 176 testing using the Benjamini Hochberg method was done if multiple comparisons were done in primary 177 analysis.

178

# 180 Results

## 181 Baseline characteristics of TBM patients and controls

182 We studied 1069 adults with TBM, 390 from Indonesia and 679 from Vietnam (Table 1). Patients were young

183 (median age 34 years), 26.6% were HIV-positive, and the majority presented with a moderately severe (55.6 %

grade II) to severe (17.0% grade III) severe disease according to the international classification.<sup>14</sup> The rate of mycobacterial confirmation was 64.1%. Sixty-day mortality, the primary endpoint in the analysis, was 21.6%.

Patients who died within 180 days from admission did so after a median of 14 days. A 14-day cut-off was

187 therefore used to distinguish early from late mortality as a secondary endpoint.

	Tuberculous meningitis	Tuberculous meningitis Non-infectious control		Cryptococcal meningitis <sup>1</sup>
	(n=1069)	(n=54)	(n=50)	(n=60)
Clinical features				
Age, years	34 (27-44)	35 (25- 44)	46 (34- 57)	33 (27- 37)
sex - % male	700 (65.5%)	30 (55.6%)	12 (60.0%)	26 (78.8%)
Glasgow Coma Scale	14 (12-15)	15 (12-15)	13 (9-14)	15 (13-15)
HIV - % positive	284 (26.6%)	11 (20.4%)	0 (0%)	60 (100%)

Tuberculous meningitis grade (%)

188 **Table 1: Patient baseline characteristics.** 

287 (27.3%)

Grade II	584 (55.6%)	-	_	-	
Grade III	179 (17.0%)	-	-	-	
Cerebrospinal fluid features					
Leukocytes- cells per µL	150 (49-336)	2 (1-3)	1900 (739-5460)	86 (24-192)	
Neutrophils- cells per µL	22 (3-99)	1 (0-1)	1527 (538-4986)	17 (6-109)	
Mononuclear cells- cells per µL	98 (38-207)	2 (1-3)	307 (134-646)	31 (6-89)	
Protein- g/L	1.46 (0.90-2.40)	0.40 (0.26-0.59)	1.90 (1.10-3.80)	0.76 (0.58-1.60)	
CSF to blood glucose ratio	0.28 (0.17-0.40)	0.60 (0.56-0.70)	0.46 (0.17-1.00)	0.50 (0.30-1.00]	
<i>M. tuberculosis</i> culture or ZN- staining or GeneXpert positive	686 (64.17%)	-	-	-	
Outcomes					
Outcome at day 60					
Alive	825 (77.2%)	-	-	-	
Deceased	231 (21.6%)	-	-	-	
Lost to follow-up	13 (1.2%)	-	-	-	
Outcome at day 180					
Alive	731 (68.4%)	-	-	-	

-

-

-

\_

-

\_

189 Legend: categorical variables are presented in N (%); Continuous variables are presented in median (IQR).

304 (28.4%)

34 (3.2%)

190 Abbreviations: CSF=cerebrospinal fluid. <sup>1</sup>Clinical metadata available for 40% of bacterial meningitis and 56% of

191 cryptococcal meningitis patients.

Deceased

Lost to follow-up

Grade I

192 There were some differences between the populations. Indonesian patients presented with more severe diseases (91.9% grade with grade II or III) than Vietnamese patients (62.2%). Also, CSF total protein, a proxy for 193 blood-CSF barrier leakage,<sup>12</sup> was higher in Indonesian (median=1.6 g/L, IQR=0.8-3.1) than Vietnamese (1.3 g/L, 194 195 IQR=0.8-2.0) patients. CSF polymorphonuclear cell counts were higher in the Indonesian than in the 196 Vietnamese patients where it showed a bimodal distribution associated to study site (Supplementary Figure 1) 197 and stratified analyses were performed taking this into account. Compared to the TBM patients, non-198 infectious controls (n=54), bacterial meningitis patients (n=50), and cryptococcal meningitis patients (n=60) 199 had a similar age range and gender distribution.

Ten metabolites showed detectable levels in >75% of patients and passed quality control, while two metabolites, 3-methoxyanthranilate and 5-hydroxyindoleacetic acid, were detected in less than 75% of patients and excluded from further analysis. Metabolite measurements showed stable concentrations over and were not affected by year of patient inclusion and duration of sample (**Supplementary Figure 2**).

204

## 205 Increased CSF tryptophan levels were associated with mortality of TBM patients independent of HIV status

Confirming our previous findings,<sup>3</sup> higher baseline CSF tryptophan levels predicted 60-day survival in patients 206 207 with TBM (HR=1.16 for each doubling in CSF tryptophan, 95%CI=1.10-1.24), all analyses corrected for age, sex 208 and HIV status, and stratified for cohort, Figure 2, Table 2). This was both true for HIV-negative (HR=1.13, 95%CI=1.05-1.21) and HIV-positive patients (HR=1.19, 95%, CI=1.07-1.33), who showed a much higher 209 mortality (Supplementary Figure 3), as reported previously.<sup>4,5</sup> Baseline CSF tryptophan was associated with 210 both early (HR=1.14, 95%CI=1.06-1.23) and late (HR=1.17, 95%CI=1.08-1.26) mortality (Supplementary Table 211 212 1). Compared to non-infectious controls, CSF tryptophan was lower. This was also observed in patients with 213 cryptococcal, but not in those with bacterial meningitis (Figure 3). Interestingly, among 17 cryptococcal 214 meningitis patients with available in-hospital mortality data in Indonesia, baseline CSF tryptophan was 215 significantly higher in those who died in hospital compared to those discharged alive (Supplementary Figure 216 4), similar as in TBM.







Figure 2 Six-months survival curve of TBM patients. Patients were stratified by CSF tryptophan concentrations
 tertiles.

221

Metabolites	HR <sup>1</sup>	95% Cl <sup>1</sup>	p-value	<b>FDR</b> <sup>2</sup>
tryptophan	1.16	1.10, 1.24	<0.001	<0.001
kynurenine	1.00	0.93, 1.07	>0.9	>0.9
kynurenic acid	1.00	0.93, 1.07	0.9	>0.9
3-hydroxyanthranilic acid	1.01	0.97, 1.05	0.6	0.9
xanthurenic acid	0.95	0.90, 1.00	0.05	0.2
quinolinic acid	0.92	0.85, 1.00	0.038	0.2
niacinamide	1.03	0.95, 1.11	0.5	0.8
3-indoleacetic acid	1.11	0.96, 1.29	0.2	0.4
N-acetylserotonin	1.01	0.94, 1.09	0.7	0.9
5-methoxytryptophol	1.11	0.93, 1.32	0.3	0.5

#### 223 Table 2 Univariate Cox regression for 60-day mortality for CSF metabolites

224 Legend: Cox regression models were stratified by cohort and adjusted by sex, age, and HIV status. Hazard ratio

225 (HR) was calculated per 2-fold increase in metabolite concentration.  $^{1}$  HR = Hazard ratio, CI = Confidence

226 interval.<sup>2</sup> FDR=False Discovery Rate; Benjamini & Hochberg correction for multiple testing.

227

# 228 CSF tryptophan levels do not reflect mycobacterial burden

We next examined if CSF tryptophan was associated with CSF mycobacterial load. We hypothesized that a low 229 baseline tryptophan might either reflect a lower bacterial load, as M. tuberculosis can produce tryptophan, or 230 231 might cause a lower bacterial load as tryptophan depletion impairs mycobacterial growth.<sup>79</sup> Instead, we found 232 a reverse, albeit weak relationship: tryptophan was higher in CSF culture negative (median=0.31 µM) than 233 culture positive (median=0.14 µM, p<0.001) TBM patients. Similarly, among patients with CSF GeneXpert-234 confirmed tuberculous meningitis patients, we did not find a correlation between CSF tryptophan and 235 quantitative PCR results (Spearman's rho=0.084, p=0.105, Supplementary Figure 5). Interestingly, within 236 patients with microbiologically confirmed TBM the effect of tryptophan was stronger (HR=1.28, 95%CI=1.17-237 1.40) than in patients with probable TBM (HR=1.07, 95%CI=0.98-1.18).

238

## 239 Relationship between cerebral and systemic metabolism and its impact on survival

Ninety-five percent of tryptophan is converted to kynurenine<sup>6</sup> and we therefore hypothesized that lower CSF tryptophan levels in TBM are caused by higher conversion to kynurenine, and that the higher CSF tryptophan associated with death could reflect reduced activity of IDO1 and other downstream enzymes. CSF kynurenine (**Figure 3**) and its downstream metabolite kynurenic acid (**Supplementary Figure 6**) were higher in TBM patients, bacterial meningitis and cryptococcal meningitis patients compared to non-infectious controls, but not significantly different between surviving and non-surviving TBM patients (**Table 2**).



246

Figure 3 CSF and plasma metabolites concentrations in TBM and controls for the tryptophan metabolites
 associated with outcome: tryptophan and kynurenine. (A) Relative concentrations based on peak ion intensity
 (B) absolute concentrations in μM.

250

251 Then, to examine the relation between cerebral and systemic tryptophan metabolism, we compared concentrations of CSF metabolites with those in plasma, measured in a subset of 300 TBM patients. In contrast 252 253 to our findings in CSF, plasma tryptophan levels were higher and kynurenine levels were lower in TBM patients compared to controls. As the CSF kynurenine metabolites positively correlated with CSF protein (Figure 4), a 254 proxy for barrier leakage<sup>12</sup>, we hypothesized that systemic leakage might be an additional source of 255 kynurenine. For a subset of metabolites, absolute quantification of metabolite levels was achieved. This 256 showed that the increase in CSF kynurenine in TBM patients ( $\Delta$  = 3.52  $\mu$ M) was much more marked than the 257 258 decrease in CSF tryptophan ( $\Delta$  = 0.39  $\mu$ M, Figure 3B). Corroborating our leakage hypothesis, the CSF-plasma 259 gradient of the kynurenine metabolites showed strong correlations with total CSF protein (Supplementary 260 Figure 7). Plasma tryptophan did not predict mortality, but plasma levels of its downstream metabolites 261 kynurenine strongly predicted mortality (Supplementary Table 2).



Figure 4 Correlation between tryptophan metabolites and with clinical and CSF parameters. Significant Spearman's correlation coefficients are presented in the correlation matrix, while the ones with not significant correlations were blank. Red indicates positive correlations, and blue indicates negative ones. The color gradient shows the strength of the associations.

267

### 268 CSF tryptophan is inversely correlated with interferon-gamma

We next looked at correlations of tryptophan metabolites and inflammation, as inflammation is a determinant 269 270 of outcome from TBM.<sup>2</sup> Out of 92 inflammatory proteins measured in CSF from 176 TBM patients from Indonesia, 80 proteins were detectable in >75% of patients. Tryptophan correlated inversely to a small cluster 271 272 of 13 cytokines, including interferon gamma (IFN-y, Supplementary Figure 8). In line with this finding, a higher CSF IFN-y has previously been shown to predict survival of Vietnamese TBM patients.<sup>4</sup> IFN-y is known to induce 273 274 IDO1<sup>15</sup>, which converts tryptophan to kynurenine. We indeed confirmed the inverse correlation between CSF 275 tryptophan and IFN-γ in our Vietnamese patients (Spearman's rho=-0.45, p<0.0001, Figure 5A), irrespective of 276 HIV-status. Different from tryptophan, the kynurenine metabolites (kynurenine, kynurenic acid, 3-277 hydroxyanthranilic acid, and quinolinic acid) correlated strongly with a large cluster of inflammatory proteins 278 including the hallmark inflammatory protein TNF- $\alpha$ , which we could again confirm in the Vietnamese patients 279 (Spearman's rho=0.30, p<0.0001, Figure 5B).

280



281

Figure 5 Associations of CSF tryptophan with IFN-γ (A) and with TNF-α (B) in 176 Indonesian (left) and 304
 (Vietnamese) TBM patients. The boxplots on the left of each plot show the association of metabolites with
 cytokines below the detection limit. Abbreviations: IFN-γ: interferon gamma, TNF-α: tumor necrosis factor
 alpha, LOD: lower limit of detection.

286

287

## 289 Discussion

290 We previously found that CSF concentrations of tryptophan were lower in HIV-negative Indonesian adults with 291 TBM compared to non-infectious controls, and that TBM patients with lower tryptophan levels had lower mortality.<sup>3</sup> In the current study we confirm these observations in a much larger cohort of HIV-negative and 292 293 positive patients from both Vietnam and Indonesia. Aiming to understand how tryptophan metabolism is 294 altered in TBM and how it might exert its effect on patient outcome, we correlated its concentrations with 295 bacterial load and CSF inflammatory markers and measured downstream metabolites both in CSF and plasma. 296 Our findings show that CSF concentrations of downstream kynurenine metabolites did not predict mortality, 297 and that higher tryptophan levels were not associated with a higher bacterial load. Also, while kynurenine 298 metabolites strongly correlated with CSF inflammatory markers and CSF protein, a marker of blood-CSF leakage, there was no association with CSF tryptophan. A higher tryptophan did however show a strong 299 300 negative correlation with IFN-y, important for immunity against mycobacteria. Collectively, these findings 301 suggest that tryptophan affects outcome from TBM within the brain rather than systemically. This is 302 potentially driven by IFN-y but not associated with nonspecific inflammation, and independent from 303 downstream tryptophan metabolism or bacterial replication. In contrast, kynurenine may affect outcome 304 systemically by leakage across the blood-brain barrier.

CSF tryptophan increases with age in individuals without central nervous system infections.<sup>16</sup> Age is known to 305 negatively impact outcome of TBM<sup>4,5</sup> and in this study, higher age was associated with higher CSF tryptophan 306 concentrations. All mortality analyses were therefore corrected for age, as well as sex and HIV-status, and 307 308 analysis was stratified for country because of the overall higher mortality in Indonesian compared to Vietnamese tuberculous meningitis patients.<sup>4,5</sup> We further tested whether higher CSF tryptophan reflected a 309 higher mycobacterial burden and refuted this hypothesis. For cryptococcal meningitis, no previous data on 310 311 cerebral tryptophan metabolism was known. These patients follow a pattern similar to TBM, with low 312 tryptophan and high kynurenine, and in a small number of cryptococcal meningitis patients, a high baseline 313 CSF tryptophan predicted mortality, similar ss for TBM.

314 Systemic tryptophan and kynurenine are transported into the brain over the large amino acid transporter 315 LAT1. In a healthy brain, systemic and CSF kynurenine positively correlate, as do CSF concentrations of tryptophan and kynurenine.<sup>16</sup> In patients with cerebral inflammation, the correlation between CSF kynurenine 316 and tryptophan can be lost, probably through increased catabolism through IDO upregulation, which also has 317 been demonstrated in the brain parenchyma of deceased TBM patients.<sup>18</sup> Although we found low CSF 318 tryptophan and high CSF kynurenine in TBM compared to healthy controls, the two did not intercorrelate and 319 320 moreover, the increase in CSF kynurenine was much larger than the decrease in CSF tryptophan and it is therefore unlikely that upregulation of IDO1 solely explains this which precludes catabolism as the sole 321 322 explanation. This suggests that increased blood to central nervous system transport as an additional 323 mechanism to IDO1 upregulation. Endothelial cells and pericytes of the blood-brain-barrier can upregulate tryptophan catabolism into kynurenine metabolites upon IFN-y stimulation.<sup>19</sup> Our findings corroborate this 324 325 hypothesis because we find a strong negative correlation between CSF IFN-y and CSF tryptophan in our 326 patients.

327 We examined whether higher CSF tryptophan concentrations reflected higher concentrations of downstream kynurenine metabolites that may have neurotoxic (quinolinic acid) or lower levels of the metabolites that may 328 have neuroprotective (kynurenic acid) properties<sup>6</sup> and refuted these hypotheses. Interestingly however, CSF 329 330 kynurenine metabolites correlated with CSF cell counts and pro-inflammatory proteins, including TNF- $\alpha$ . Kynurenine is sensed by the aryl hydrocarbon receptor (AhR), which is important for the upregulation of TNF 331 among other pro-inflammatory cytokines in a mouse model,<sup>20</sup> in line with our CSF findings. The increased CSF 332 333 kynurenine levels we found in TBM have been reported before in bacterial meningitis<sup>21,22</sup> and in cerebral malaria<sup>23</sup> and in plasma from pulmonary TB patients.<sup>17</sup> Of interest, nicotinamide can inhibit *M. tuberculosis* 334 growth, and can compete with isoniazid for antimycobacterial effects.<sup>24</sup> We did however not find a 335 detrimental effect of a higher nicotinamide, possibly because of its complex biology, i.e. it can also be 336 produced by *M. tuberculosis* when human dietary niacin intake is limited.<sup>25</sup> 337

Strengths of our study include the large numbers of clinically well-phenotyped patients from multiple
 independent study sites in Indonesia and Vietnam, including a significant proportion of HIV-positive patients.
 We moreover used a sensitive triple quadrupole (QQQ) mass spectrometry method specifically designed to

341 accurately target the tryptophan metabolites. Absolute quantification of a subset of metabolites further 342 facilitated interpretation. Due to differences in polarity of the downstream tryptophan metabolites, we could 343 not measure the complete tryptophan pathway. The availability of CSF at baseline only, limits our ability to 344 understand how changes in tryptophan metabolism influence mortality. And we infer our observations from lumbar CSF, which reflects biological processes from both the blood and the brain. The use of ventricular CSF 345 346 and potentially animal models, could help establishing what processes in the brain parenchyma take place. 347 Animal studies are warranted to see whether pharmacological induction of IDO1 (for instance with recombinant IFN-y), or inhibitory tryptophan analogues<sup>26</sup> should be priorities as adjuvant therapeutic 348 349 candidates for future personalized trials.

In summary, we confirm the importance of CSF tryptophan to outcome from HIV-negative and HIV-positive adults with TBM, independent from downstream kynurenine metabolism, bacterial load and inflammation. We additionally show the potential importance of systemic kynurenine as a predictor of mortality. Better understanding of the metabolic pathways associated with TBM may lead to more targeted therapies, as adjuvant immunotherapy may modulate the aberrant metabolic pathways and thus improve outcome.

355

# 356 Materials availability

The clinical metadata and LC-MS data before pre-processing is available as Supplementary File to this manuscript.

359

## 360 Acknowledgements

361 The authors thank the neurology residents and Tiara Pramaesya, Sofia Immaculata, Putri Andini, Sri Margi, 362 Rani Trisnawati and Shehika Shulda of the tuberculous meningitis study team for monitoring patients and data 363 management; Lidya Chaidir and Jessi Annisa for mycobacterial diagnostics; the director of the Hasan Sadikin 364 General Hospital, Bandung, Indonesia, for accommodating the research. We also express our gratitude to our funders: This study was supported by National Institutes of Health (R01Al145781), the Wellcome Trust 365 366 (110179/Z/15/Z and 206724/Z/17/Z). Previous establishment of the cohorts in Indonesia was supported by the 367 Direktorat Jendral Pendidikan Tinggi (BPPLN fellowship to SD) and the Ministry of Research, Technology, and Higher Education, Indonesia (PKSLN grant to THA, RR, and SD), and United States Agency for International 368 369 Development (PEER Health grant to RR). The funders had no role in study design, data collection and analysis, 370 decision to publish, or preparation of the manuscript.

## 372 **References**

- 1 Dodd PJ, Osman M, Cresswell FV, *et al.* The global burden of tuberculous meningitis in adults: A modelling
   study. *Plos Global Public Heal* 2021; 1: e0000069.
- 2 Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol 2017; 13: 581–98.
- 377 3 Laarhoven A van, Dian S, Aguirre-Gamboa R, *et al.* Cerebral tryptophan metabolism and outcome of
- tuberculous meningitis: an observational cohort study. *The Lancet Infectious Diseases* 2018; 18: 526–35.
- 4 Thuong NTT, Heemskerk D, Tram TTB, *et al.* Leukotriene A4 Hydrolase Genotype and HIV Infection Influence
   Intracerebral Inflammation and Survival From Tuberculous Meningitis. *Journal of Infectious Diseases* 2017;
   215: 1020–8.
- 5 Laarhoven A van, Dian S, Ruesen C, *et al.* Clinical Parameters, Routine Inflammatory Markers, and LTA4H
   Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. *J Infect Dis* 2017; 215: 1029–39.
- 6 Lovelace MD, Varney B, Sundaram G, *et al.* Recent evidence for an expanded role of the kynurenine pathway
   of tryptophan metabolism in neurological diseases. *Neuropharmacology* 2017; 112: 373–88.
- 7 Heemskerk AD, Bang ND, Mai NTH, *et al.* Intensified Antituberculosis Therapy in Adults with Tuberculous
   Meningitis. *N Engl J Med* 2016; 374: 124–34.
- 8 Thwaites GE, Nguyen DB, Nguyen HD, *et al.* Dexamethasone for the treatment of tuberculous meningitis in
   adolescents and adults. *N Engl J Med* 2004; 351: 1741–51.
- 391 9 Rohlwink UK, Chow FC, Wasserman S, *et al.* Standardized approaches for clinical sampling and endpoint
   392 ascertainment in tuberculous meningitis studies. *Wellcome Open Res* 2019; 4: 204.
- 10 Thuong NTT, Vinh DN, Hai HT, et al. Pretreatment Cerebrospinal Fluid Bacterial Load Correlates With
   Inflammatory Response and Predicts Neurological Events During Tuberculous Meningitis Treatment. Journal of
   Infectious Diseases 2019; 219: 986–95.
- 11 Assarsson E, Lundberg M, Holmquist G, *et al.* Homogenous 96-plex PEA immunoassay exhibiting high
   sensitivity, specificity, and excellent scalability. *PLoS ONE* 2014; 9: e95192.
- Svensson EM, Dian S, Brake LT, *et al.* Model-based meta-analysis of rifampicin exposure and mortality in
   Indonesian tuberculosis meningitis trials. *Clin Infect Dis* 2019; published online Oct 30.
   DOI:10.1093/cid/ciz1071.
- 401 13 Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing.
   402 Vienna, Austria, 2022 <u>https://www.R-project.org/.</u>
- 403 14 Thwaites GE, Simmons CP, Quyen NTH, *et al.* Pathophysiology and prognosis in vietnamese adults with
   404 tuberculous meningitis. *Journal of Infectious Diseases* 2003; 188: 1105–15.
- 405 15 Zhang YJ, Reddy MC, loerger TR, *et al.* Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell 406 Mediated Killing. *Cell* 2013; 155: 1296–308.
- 407 16 Hestad KA, Engedal K, Whist JE, Farup PG. The Relationships among Tryptophan, Kynurenine, Indoleamine
  408 2,3-Dioxygenase, Depression, and Neuropsychological Performance. *Front Psychol* 2017; 8: 1561.
- 409 17 Weiner J, Maertzdorf J, Sutherland JS, *et al.* Metabolite changes in blood predict the onset of tuberculosis.
  410 *Nat Comms* 2018; : 1–12.
- 18 Kumar GS, Venugopal AK, Selvan LDN, Marimuthu A, Keerthikumar S. Gene Expression Profiling of
   Tuberculous Meningitis. *JPB* 2011; 04. DOI:10.4172/jpb.1000174.
- 413 19 Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood–brain–
- barrier cells: implications for immune tolerance & neurotoxicity. *J Neurochem* 2008; 105: 1346–57.

- 20 Moura-Alves P, Faé K, Houthuys E, *et al.* AhR sensing of bacterial pigments regulates antibacterial defence. *Nature* 2014; 512: 387–92.
- 21 Coutinho LG, Christen S, Bellac CL, *et al.* The kynurenine pathway is involved in bacterial meningitis. *J Neuroinflamm* 2014; 11: 169.
- 22 Sühs K-W, Novoselova N, Kuhn M, *et al.* Kynurenine Is a Cerebrospinal Fluid Biomarker for Bacterial and
  Viral Central Nervous System Infections. *J Infect Dis* 2019; 220: 127–38.
- 421 23 Medana IM, Day NPJ, Salahifar-Sabet H, *et al.* Metabolites of the kynurenine pathway of tryptophan
- 422 metabolism in the cerebrospinal fluid of Malawian children with malaria. *Journal of Infectious Diseases* 2003;
  423 188: 844–9.
- 424 24 Murray MF. Nicotinamide: An Oral Antimicrobial Agent with Activity against Both Mycobacterium
- 425 tuberculosis and Human Immunodeficiency Virus. *Clin Infect Dis* 2003; 36: 453–60.
- 426 25 Adu-Gyamfi CG. Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or
  427 Supporting Act in the Tuberculosis and HIV Pas-de-Deux? *Front Cell Infect Microbiol* 2019; 9: 1–12.
- 428 26 Wang X, Mehra S, Kaushal D, Veazey RS, Xu H. Abnormal Tryptophan Metabolism in HIV and
- 429 Mycobacterium tuberculosis Infection. *Front Microbiol* 2021; 12: 666227.

430



440 **Supplementary Figure 1 CSF parameters of TBM patients in Indonesia and Vietnam.** Distributions of 441 leukocytes, polymorphonuclear cells, mononuclear cells, protein, and the ratio of CSF/blood glucose in 442 Indonesian (purple) and Vietnamese (yellow) patients are depicted by violin plots.





Supplementary Figure 2 Stability of metabolites over-time. The concentrations of tryptophan metabolites (in
 log2 scale) were measured in CSF samples from Indonesian (purple) and Vietnamese (yellow) TBM patients
 were recruited between 2007-2018.





454 455

456 **Supplementary Figure 3 Six-month survival curve of TBM patients stratified by HIV status.** Patients were 457 stratified by tertiles based on CSF tryptophan concentrations (red=high tryptophan, gray=intermediate 458 tryptophan, blue=low tryptophan)

460



462 Supplementary Figure 4 In-hospital mortality for 17 HIV-positive patients with cryptococcal meningitis.

463

464



466 **Supplementary Figure 5 CSF tryptophan distributions according to mycobacterial load.** (A) comparing CSF 467 culture negative versus positive patients and (B) among patients with a positive CSF Xpert, in culture positive 468 and culture negative TBM patients, CSF tryptophan was associated with CSF Xpert Ct-values from a low (high 469 Ct-value) to low (low Ct-value) load.

470





**Supplementary Figure 6 Boxplots of CSF and plasma metabolites concentrations in TBM and controls.** 475 Relative concentrations based on peak ion intensities are shown. CSF and plasma concentrations are not

*directly comparable.* 

478



480 Supplementary Figure 7 Associations between CSF/plasma metabolite ratios (y-axis) and CSF protein levels

(as a proxy of CSF barrier leakage, x-axis). Of note, 71 patients had undetectable plasma levels of 3 indolacetic acid and were removed from this graph.

483

479



Supplementary Figure 8 Correlation between CSF tryptophan metabolites and inflammatory markers measured with O-link. Inflammatory markers were clustered based on their correlation coefficients using hierarchical clustering. Red indicates positive correlation, and blue indicated negative correlation.

	Early mortality (day 0-14)			Late mortality (day 14-180)					
Metabolite	HR <sup>1</sup>	95% Cl <sup>1</sup>	p-value	FDR <sup>2</sup>	HF	₹1	95% Cl <sup>1</sup>	p-value	FDR <sup>2</sup>
tryptophan	1.14	1.06, 1.23	<0.001	0.005	1.1	7	1.08, 1.26	<0.001	<0.001
kynurenine	1.03	0.95, 1.13	0.4	0.6	1		0.91, 1.10	>0.9	>0.9
kynurenic acid	1.05	0.96, 1.14	0.3	0.5	0.9	95	0.86, 1.04	0.3	0.5
3-hydroxyanthranilic acid	1.02	0.97, 1.06	0.5	0.6	1.(	)1	0.96, 1.06	0.6	0.7
xanthurenic acid	0.96	0.90, 1.03	0.2	0.5	0.9	96	0.89, 1.04	0.3	0.5
quinolinic acid	0.89	0.81, 0.98	0.02	0.1	0.	9	0.81, 1.00	0.052	0.2
niacinamide	1.02	0.92, 1.12	0.7	0.7	1.(	)5	0.95, 1.16	0.3	0.5
3-indoleacetic acid	1.1	0.92, 1.32	0.3	0.5	1.1	8	0.97, 1.43	0.093	0.2
N-acetylserotonin	1.05	0.96, 1.14	0.3	0.5	0.9	96	0.88, 1.06	0.4	0.5
5-methoxytryptophol	1.09	0.87, 1.35	0.5	0.6	1.2	29	1.04, 1.59	0.02	0.1

# 495 Supplementary Table 1 Univariate Cox regression for influence CSF metabolites on early and late mortality

496 Cox regression models were stratified by sites and adjusted by age, sex, and GCS. <sup>1</sup> HR = Hazard Ratio, Cl =

**497** *Confidence Interval.* <sup>2</sup> *Benjamini & Hochberg correction for multiple testing.* 

498

499

500

# 501 Supplementary Table 2 Univariate Cox regression for influence of plasma metabolites on 60-day mortality

Metabolite	HR <sup>1</sup>	95% Cl <sup>1</sup>	p-value	FDR <sup>2</sup>	
Tryptophan	0.8	0.56, 1.16	0.2	0.4	
Kynurenine	1.54	1.22, 1.93	<0.001	0.002	
kynurenic acid	1.2	1.01, 1.43	0.036	0.2	
3-hydroxyanthranilic acid	1.13	1.00, 1.28	0.045	0.2	
xanthurenic acid	1.11	0.98, 1.25	0.1	0.3	
quinolinic acid	0.99	0.88, 1.12	0.9	0.9	
Niacinamide	0.92	0.79, 1.07	0.3	0.4	
3-indoleacetic acid	1.04	0.97, 1.12	0.3	0.4	
N-acetylserotonin	1.05	0.91, 1.22	0.5	0.6	
5-methoxytryptophol	1.04	0.85, 1.28	0.7	0.8	

502 Plasma tryptophan metabolites were measured in a subset 300 patients. Cox regression models were stratified

503 by sites and adjusted by age, sex, and GCS. <sup>1</sup> HR = Hazard Ratio, CI = Confidence Interval. <sup>2</sup> Benjamini & Hochberg correction for multiple testing

504 *Hochberg correction for multiple testing.*